Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Investigating the Impact of Treadmill-integrated Virtual Reality Training on Walking Outside the Clinic

9. november 2026 oppdatert av: Shepherd Center, Atlanta GA

Investigating the Acute and Long-term Effects of Treadmill-integrated Virtual Reality (VR) Training on Real-World Mobility and Fall-Related Outcomes in People With Multiple Sclerosis

This study will test whether a treadmill-based virtual reality walking program is safe, practical, and helpful for people with multiple sclerosis (MS). Participants will complete a 6-week training program and wear smart socks that measure how they walk before, during, and after the program. The study will also track changes in balance, fatigue, fall risk, fear of falling, confidence with walking, and overall quality of life.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

People with multiple sclerosis (MS) often have trouble with walking and balance, which can increase the risk of falls and make daily life harder. While therapy can improve walking in a clinic, it is not always clear if those improvements carry over to real life at home or in the community. In addition, most walking tests are done over short periods and may not show how a person moves throughout the day. This study will look at new ways to better understand and improve walking in everyday settings. Researchers will use a treadmill-based virtual reality program, along with smart socks that track walking during daily activities. This approach will help show how people respond to training and whether those changes last outside the clinic. Standard care for people with MS usually includes physical therapy and clinic-based walking tests, but these may miss important changes in daily movement.

Participants will be asked to provide basic health information and complete surveys about their walking, fatigue, balance, thinking, and quality of life at different times during the study. They will also complete simple walking and balance tests to measure their mobility. As part of the study, participants will take part in a 6-week treadmill-based virtual reality training program, with two sessions each week. During the study, they will wear smart socks that collect information about how they walk in their daily lives, including before, during, and after the training program. These socks will track how often they walk, how steady they are, and how their walking changes over time. After the training ends, participants will continue wearing the socks for several weeks so researchers can see if improvements last. The results will help researchers learn if this approach can improve walking, lower fall risk, and support better mobility and quality of life for people living with MS.

Studietype

Intervensjonell

Registrering (Antatt)

10

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Georgia
      • Atlanta, Georgia, Forente stater, 30309
        • Rekruttering
        • Shepherd Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Julie F Stowell, DPT

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Have a clinically confirmed diagnosis of multiple sclerosis (MS).
  • Be 18 years of age or older.
  • Demonstrate ≥10% variability in stride length, step length, or gait asymmetry.
  • Can ambulate without an assistive device, with a unilateral, or with a bilateral assistive device.
  • Demonstrate no more than mild cognitive impairment, indicated by the Mini-Mental State Exam (score >19).
  • Possess adequate cognitive function to understand and follow research instructions.
  • Be able to safely participate in the study and training procedures as determined by study staff.
  • Be fluent in English and able to communicate discomfort, fatigue, or pain in English.
  • Be able to travel to Shepherd Center to complete key assessment points in-person and for in-person training sessions twice per week.

Exclusion Criteria:

  • Have a diagnosis of any other neurological condition or recent orthopedic conditions that affects gait, balance, or mobility.
  • Exhibit <10% variability in stride length, step length, or gait asymmetry.
  • Are unable to ambulate (i.e. wheelchair bound or bedbound individuals).
  • Have legal blindness or severe visual impairment that would interfere with virtual reality engagement or safe ambulation.
  • Have a body weight exceeding 300 lbs., which exceeds the safety limits of the treadmill and body weight support system.
  • Have uncontrolled or untreated hypertension, hypotension, or angina.
  • Have a past or current history of epilepsy or any other type of seizure disorder, whether controlled or uncontrolled.
  • Have undergone major surgery within the past 6 months or hospitalization within the past 3 months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1

Gait training

6-week training program with 2 training sessions each week

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

step length (m)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

stride length (m)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

step time (s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

single support time (s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

double support time (s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

gait cycle (s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

cadence (steps/s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

stance time (s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

speed(m/s)

Initial visit to the end of the program in 12 weeks
Spatiotemporal metrics of gait
Tidsramme: Initial visit to the end of the program in 12 weeks

swing time (s)

Initial visit to the end of the program in 12 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fear of falling (FOF)
Tidsramme: Surveys will be conducted at the initial visit, week 2, 5, 8, and 12.

FOF as determined by Falls Efficacy Scale-International (FES-I); Scale: Not at all concerned = 1, Somewhat concerned = 2, Fairly concerned = 3, Very concerned = 4; Lowest score = 16, Highest score = 64, lower scores indicated less FOF (better), higher scores indicated more FOF (worse), total score divided by 64.

Surveys will be conducted at the initial visit, week 2, 5, 8, and 12.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. juli 2026

Primær fullføring (Antatt)

27. april 2027

Studiet fullført (Antatt)

27. april 2027

Datoer for studieregistrering

Først innsendt

2. november 2026

Først innsendt som oppfylte QC-kriteriene

9. november 2026

Først lagt ut (Faktiske)

10. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Shepherd Center will publish findings as appropriate and will maintain confidential records as necessary.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere